Pacira BioSciences, Inc. (PCRX) News
Filter PCRX News Items
PCRX News Results
|Loading, please wait...|
PCRX News Highlights
- For PCRX, its 30 day story count is now at 18.
- Over the past 24 days, the trend for PCRX's stories per day has been choppy and unclear. It has oscillated between 1 and 4.
- AG, BEAT and MASI are the most mentioned tickers in articles about PCRX.
Latest PCRX News From Around the Web
Below are the latest news stories about Pacira BioSciences Inc that investors may wish to consider to help them evaluate PCRX as an investment opportunity.
Pacira's (PCRX) earnings surpass estimates in the fourth quarter of 2021 while revenues are slightly above estimates.
Pacira BioSciences press release (NASDAQ:PCRX): Q4 Non-GAAP EPS of $0.97 beats by $0.14. Revenue of $159.19M (+21.5% Y/Y) beats by $1.77M. “The acquisition of Flexion Therapeutics combined with record EXPAREL sales resulted in a pivotal year for Pacira, allowing us to enter 2022 in the strongest financial position in our...
The following slide deck was published by Pacira BioSciences, Inc. in conjunction with their 2021 Q4 earnings call....
Pacira (PCRX) delivered earnings and revenue surprises of 16.87% and 0.27%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
— Anesthesia-driven regional approaches drive record EXPAREL sales of $507 million in 2021 —— Full-year GAAP net income of $42 million and adjusted EBITDA of $204 million —— More than 10 million patients have received EXPAREL since launch —— Conference call today at 8:30 a.m. ET — TAMPA, Fla., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today reported financial re
Pacira (PCRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Offer Insights on Healthcare Companies: Masimo (MASI), Pacira Pharmaceuticals (PCRX) and Monopar Therapeutics Inc (MNPR)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Masimo (MASI – Research Report), Pacira Pharmaceuticals (PCRX – Research Report) and Monopar Therapeutics Inc (MNPR – Research Report). Masimo (MASI) BTIG analyst Marie Thibault maintained a Hold rating on Masimo today. The company's shares closed last Tuesday at $228.84. According to TipRanks.
Needham analyst Serge Belanger maintained a Buy rating on Pacira Pharmaceuticals (PCRX – Research Report) today and set a price target of $84.00. The company's shares closed last Tuesday at $64.74. According to TipRanks.com, Belanger is a 3-star analyst with an average return of 1.9% and a 41.6% success rate. Belanger covers the Healthcare sector, focusing on stocks such as Clarus Therapeutics Holdings, Collegium Pharmaceutical, and KalVista Pharmaceuticals. Currently, the analyst consensus on Pacira Pharmaceuticals is a Strong Buy with an average price target of $83.88.
TAMPA, Fla., Feb. 16, 2022 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX) today announced that it will report its fourth quarter and year ended December 31, 2021 financial results before the open of the U.S. markets on Thursday, February 24, 2022. Following the release, the company will host a live conference call and webcast at 8:30 a.m. ET. To participate in the conference call, dial 1-888-771-4371 and provide the passcode 50282786. International callers may dial 1-847-585-4405 and
Pacira BioSciences Reports Preliminary Net Product Sales for EXPAREL and iovera° of $37.3 Million for January 2022
-- EXPAREL average daily sales for January 2022 were 104% of January 2021 --TAMPA, Fla., Feb. 15, 2022 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today reported preliminary unaudited net product sales for EXPAREL® (bupivacaine liposome injectable suspension) and iovera° for the month of January 2022. EXPAREL net product sales were $36.3 million, compared with $34.9 million for